We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Implant Coatings Make Them More Biocompatible

By HospiMedica International staff writers
Posted on 09 Jul 2020
A new method of applying anti-inflammatory substances can inhibit undesirable inflammatory reactions to implants, claims a new study.

Researchers at the Martin Luther University Halle-Wittenberg (MLU; Halle-Wittenberg; Germany), the University of Niš (Serbia), and other institutions conducted a study to examine the anti-inflammatory properties of surface coatings made of either hyaluronic acid (HA) or heparin (H) in combination with chitosan, prepared as multilayers through a layer-by-layer deposition technique. More...
The properties of the glycosaminoglycan (GAG)-modified surfaces were then characterized in terms of surface topography, thickness, and wettability.

The results showed a higher thickness and hydrophilicity after multilayer formation. The multilayers containing either HA or H dampened the inflammatory response visible by reduced adhesion, formation of multinucleated giant cells and interleukin release, and a significant decrease in macrophages on GAG-based multilayers, with the macrophages able to associate with and take up both HA and H. Overall, the heparin-based multilayers demonstrated the most suppressive effect on macrophage activation after implantation of medical devices. The study was published on May 25, 2020, in the International Journal of Molecular Sciences.

“The immune system attracts various cells that try to isolate or remove the foreign entity; these include macrophages. This is kind of tricky, because we obviously do not want to completely turn off the immune system as its processes are vital for healing wounds and killing pathogens,” said senior author Professor Thomas Groth, PhD, of the MLU Institute of Pharmacy. “Both heparin and hyaluronic acid prevent the release of certain pro-inflammatory messenger substances. Heparin is even more effective because it can be absorbed by macrophage cells.”

Chitosan is a linear polysaccharide composed of randomly distributed glucoseamine deacetylated unit and acetylated units. It is made by treating shrimp and other crustacean shells with the alkali sodium hydroxide. Chitosan also has a number of commercial uses, such as a seed treatment and biopesticide, helping plants to fight off fungal infections. In winemaking it can be used as a fining agent, and it can also be used in self-healing polyurethane paint coating.

Related Links:
Martin Luther University Halle-Wittenberg
University of Niš



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.